Vaccines-2013 - OMICS Group

Recommendations

Info

Abebe Mengesha et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USASafety and potency test for experimental cell culture based anti-rabies vaccine produced in EthiopiaAbebe Mengesha, Newayeselassie B, Hurrisa B, Beyene M, Denis B, Artem M, Kerga S and Urga KEthiopian Health and Nutrition Research Institute, EthiopiaObjective: To determine potency and safety of the experimental formalin inactivated cell culture based anti-rabies vaccines.Methodology:Mice: 10-16 g weight, 2 weeks age mice with identical sex were used.Inactivation: The viral suspension was thawed and formalin inactivation was done using a concentration of 1:5000 vol/vol andincubated at 37 0 C for 48 h with shaking twice a day.Safety Test: Safety test determines the presence of residual virulent virus and any bacterial contamination in the vaccine.Presences of residual virus were done on mice and any other contamination tested bacteriologically.Potency Test: Potency test determines the degree of protection conferred by the vaccine in immunized mice challenged withchallenge virus strain. This test was performed using National Institutes of Health (NIH) test.Immunization: Mice were immunized at day 0 and 7 with five different concentrations for test vaccine and four differentconcentrations for control vaccine, 16 mice in each dilution. The control vaccine used was Vero Rab vaccine which wasproduced by Sanofi Pasteur.Challenge Test: Standard CVS strain from CDC was used for challenging. Mice were challenged on 14 th day of immunizationwith challenge virus strain (CVS-11) of 25 MLD 50/0.03 ml. The mice were observed for 14 days.Result: Potency of our test vaccine calculated using NIH test was 8.32 IU for ERA and 2.5 IU for PV results were obtained.Conclusion: Based on the result it can be concluded that, both of our vaccines have higher potency than required for single doseof anti rabies vaccine. Therefore these can be diluted to standard vaccine potency and be used for animal immunization.agagurmu@yahoo.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 118
Afshineh Latifynia et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAA comparison of effect of new formulation antigen on Th1 & Th2 cytokine profiles, and,their relationship with spleen' white pulp size expansion in balb/c mice, post challengingwith Leishmania majorAfshineh Latifynia, A. Khamesipour, Gharagozlou M. J., Mohebali M., Hajaran H. and N. KhansariTehran University of Medical Sciences, Islamic Republic of IranHuman leishmaniasis is distributed worldwide, but mainly in the tropics and subtropics, with a prevalence of 12 millioncases and an approximately incidence of 0.5 million cases of VL and 1.5 million cases of cutaneous leishmaniasis (CL).Leishmania parasites are vector-born protozoan pathogens found in tropical and subtropical regions of both the old and newworld. The disease in human can be divided into cutaneous, visceral, and mucosal syndromes. The aim of this study was toconduct more experiments over our previous new formulation modify leishmania major antigen that had satisfactory results,before.In this study we have made preliminarily new vaccine with the same methodology again and selected two injection doses(100 & 200 μg/0.1ml), three injection groups: Leishmania plus BCG (LB), Leishmania plus new adjuvant (Teucrium Polium)[LT],leishmania plus BCG and Teucrium Polium (LBT),and one susceptible mice(Balb/c) and measure two type cytokines: Th1(IFN-γ,IL-12) and Th2(IL-4,IL-10) and expansion of white pulp size after challenge with live leishmania. Results show that both dosesover LBT group have highest IL-12, lowest IL-10 and highest increasing in spleen’s white pulp size, whether; other two groupshave lower IL-12, higher IL-10 and lowest increasing in spleen’s white pulp size in susceptible mice. When all of the three groupsand two genius Balb/c mice (male/female), considered, and without consideration injection dose, the largest white pulp size wereseen in female Balb/c LBT group, and smallest white pulp size were seen in male Balb/c LT group).Conclusion: Our study show that in Balb/c mice, best injection group that produced highest IL-12 and lowest IL-10 and highestincreasing in spleen’s white pulp size, is LBT group, which have significant differences with others. This finding show that,adjuvant BCG both Teucrium have synergic effect with together.BiographyAfshineh Latifynia has completed her M.Sc. at the age 33 years from Tehran University and is studying M.Phil. courses of her Ph.D. in PrimaryImmunodefi ciency Research Center in Faculty of Medicine, Tehran University of Medical Sciences (TUMS). She has published more than 10 papersin PubMed, Scopus, and one of them had choice as ten top articles in 2010, and top twenty in 2011, and another one, as twenty fi ve hot tops articlein 2010. She has three articles under review and also has two articles in the pre submit step. She is teacher and researcher in the Department ofImmunology, Faculty of Medicine, TUMS, and her Ph.D. thesis is about MSMD (Mendelian Susceptibility Mycobacterium Disease).alatifynia@sina.tums.ac.irJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 119
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 117: 111 th OMICS Group Conference3 rd I
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142: 111 th OMICS Group Conference3 rd I
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?